Last reviewed · How we verify
Risankizumab Dose B
Risankizumab Dose B is a Small molecule drug developed by AbbVie. It is currently in Phase 1 development.
Risankizumab is being studied in clinical trials for various skin conditions, including Chronic Spontaneous Urticaria, Hidradenitis Suppurativa, Psoriasis, Atopic Dermatitis, and CTCL/Mycosis Fungoides. Risankizumab is an interleukin-23 (IL-23) inhibitor, according to ChEMBL, which suggests its mechanism of action.
-
Baseline phase 1 → approval rate
+9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas). -
Big-pharma sponsor
+3.0pp
AbbVie is a top-20 pharma sponsor — historical approval rates run ~3pp above average due to scale, regulatory experience, and trial-design quality.
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2033–2036 | — |
| EMA | EU | 2034–2037 | +0.7 yr |
| MHRA | GB | 2034–2037 | +0.7 yr |
| Health Canada | CA | 2034–2038 | +0.9 yr |
| TGA | AU | 2034–2038 | +1.2 yr |
| PMDA | JP | 2034–2038 | +1.5 yr |
| NMPA | CN | 2035–2039 | +2.3 yr |
| MFDS | KR | 2034–2038 | +1.4 yr |
| CDSCO | IN | 2034–2039 | +1.8 yr |
| ANVISA | BR | 2035–2039 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Risankizumab Dose B |
|---|---|
| Sponsor | AbbVie |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Study to Assess Adverse Events, Change in Disease Activity, and How Intravenous and Subcutaneous Risankizumab Moves Through the Body of Pediatric Participants With Moderately to Severely Active Crohn's Disease (PHASE3)
- Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's Disease (PHASE2)
- A Study to Assess How Intravenous and Subcutaneous Administrations of Risankizumab Moves Through the Body of Healthy Adult Participants (PHASE1)
- A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) (PHASE4)
- Describing Treatment Patterns and Creating an Updated Treatment Flow in an Ulcerative Colitis Population
- A Study to Learn More About How Risankizumab Works in Young Participants With Ulcerative Colitis (PHASE3)
- A Study to Assess the Bioavailability of Risankizumab Following Subcutaneous Administration With Prefilled Pen Relative to a Prefilled Syringe in Healthy Adult Participants (PHASE1)
- Study of Targeted Therapies for the Treatment of Adult Participants With Active Psoriatic Arthritis (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Risankizumab Dose B CI brief — competitive landscape report
- Risankizumab Dose B updates RSS · CI watch RSS
- AbbVie portfolio CI
Frequently asked questions about Risankizumab Dose B
What is Risankizumab Dose B?
Who makes Risankizumab Dose B?
What development phase is Risankizumab Dose B in?
Related
- Manufacturer: AbbVie — full pipeline
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing